Trade Report: The United Therapeutics Corp. (UTHR) to Post FY2016 Earnings of $16.09 Per Share, Leerink Swann Forecasts

The United Therapeutics Corp. (UTHR) to Post FY2016 Earnings of $16.09 Per Share, Leerink Swann Forecasts

United Therapeutics Corp. (NASDAQ:UTHR) – Leerink Swann increased their FY2016 earnings per share estimates for shares of United Therapeutics Corp. in a research report issued on Thursday. Leerink Swann analyst J. Schwartz now forecasts that the brokerage will post earnings per share of $16.09 for the year, up from their previous estimate of $15.56. Leerink Swann also issued estimates for United Therapeutics Corp.’s Q4 2016 earnings at $3.31 EPS, FY2017 earnings at $12.32 EPS and FY2018 earnings at $10.83 EPS.

A number of other equities research analysts also recently weighed in on the company. Cowen and Company set a $144.00 price target on United Therapeutics Corp. and gave the stock a “buy” rating in a research note on Thursday. Ladenburg Thalmann raised United Therapeutics Corp. from a “neutral” rating to a “buy” rating and raised their price target for the stock from $128.00 to $138.00 in a research note on Friday. Zacks Investment Research downgraded United Therapeutics Corp. from a “buy” rating to a “hold” rating in a research note on Thursday, October 20th. Argus reaffirmed a “hold” rating on shares of United Therapeutics Corp. in a research note on Tuesday, August 23rd. Finally, JPMorgan Chase & Co. cut their price target on United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating for the company in a research note on Friday, July 29th. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. United Therapeutics Corp. currently has a consensus rating of “Hold” and a consensus target price of $137.17.

United Therapeutics Corp. (NASDAQ:UTHR) opened at 118.14 on Monday. The stock has a market capitalization of $5.01 billion, a PE ratio of 8.00 and a beta of 1.42. United Therapeutics Corp. has a 1-year low of $97.52 and a 1-year high of $164.04. The stock’s 50 day moving average price is $119.58 and its 200 day moving average price is $116.21.

United Therapeutics Corp. (NASDAQ:UTHR) last released its earnings results on Thursday, October 27th. The biotechnology company reported $4.36 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.38 by $0.98. The company earned $408.20 million during the quarter, compared to analysts’ expectations of $400.58 million. United Therapeutics Corp. had a return on equity of 42.62% and a net margin of 44.40%. The business’s revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the business posted $3.55 EPS.

In other news, CEO Martine A. Rothblatt sold 1,282 shares of United Therapeutics Corp. stock in a transaction that occurred on Thursday, October 20th. The stock was sold at an average price of $113.30, for a total transaction of $145,250.60. Following the sale, the chief executive officer now owns 1,422 shares of the company’s stock, valued at approximately $161,112.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,272 shares of United Therapeutics Corp. stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of $117.06, for a total value of $148,900.32. Following the sale, the chief executive officer now directly owns 1,412 shares in the company, valued at approximately $165,288.72. The disclosure for this sale can be found here. 7.50% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP raised its stake in shares of United Therapeutics Corp. by 4.0% in the second quarter. GSA Capital Partners LLP now owns 32,696 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 1,267 shares during the last quarter. Scopia Capital Management LP raised its stake in shares of United Therapeutics Corp. by 48.1% in the first quarter. Scopia Capital Management LP now owns 4,219,281 shares of the biotechnology company’s stock valued at $470,154,000 after buying an additional 1,370,698 shares during the last quarter. Arizona State Retirement System raised its stake in shares of United Therapeutics Corp. by 6.0% in the first quarter. Arizona State Retirement System now owns 24,926 shares of the biotechnology company’s stock valued at $2,778,000 after buying an additional 1,400 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its stake in shares of United Therapeutics Corp. by 2.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 43,247 shares of the biotechnology company’s stock valued at $4,819,000 after buying an additional 927 shares during the last quarter. Finally, Bellevue Group AG purchased a new stake in shares of United Therapeutics Corp. during the first quarter valued at $2,325,000.

About United Therapeutics Corp.

Related posts

Leave a Comment